A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
A phase 3 trial of Abemaciclib and Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) is a phase 3 interventional study registered as NCT05288166 by Eli Lilly and Company, with 925 participants enrolled, started 2022-04-14 and due to reach its primary completion in 2024-02-15. Interventions recorded: Abemaciclib, Abiraterone, Prednisone or Prednisolone and Placebo for Abemaciclib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialCAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Shares Prednisone, Abemaciclib, Eli Lilly (incl. Loxo), Prostate cancer.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Prostate cancer and the tag pipeline.